Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
7.44
+0.05 (0.68%)
At close: May 6, 2026, 4:00 PM EDT
7.16
-0.28 (-3.76%)
After-hours: May 6, 2026, 7:32 PM EDT
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 533 employees as of December 31, 2025. The number of employees increased by 165 or 44.84% compared to the previous year.
Employees
533
Change (1Y)
165
Growth (1Y)
44.84%
Revenue / Employee
$408,597
Profits / Employee
-$449,432
Market Cap
447.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 533 | 165 | 44.84% |
| Dec 31, 2024 | 368 | 165 | 81.28% |
| Dec 31, 2023 | 203 | -87 | -30.00% |
| Dec 31, 2022 | 290 | 12 | 4.32% |
| Dec 31, 2021 | 278 | -14 | -4.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsVNDA News
- 3 hours ago - Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 4 hours ago - Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - PRNewsWire
- 2 days ago - Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - PRNewsWire
- 7 days ago - Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - PRNewsWire
- 8 days ago - Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - PRNewsWire
- 14 days ago - Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors - PRNewsWire
- 27 days ago - Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines - PRNewsWire
- 4 weeks ago - Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PRNewsWire